Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Vanda Pharmaceuticals Inc's Business Segments
Vanda Pharmaceuticals Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
Product
Total Revenue
$ 52
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2026
- Product100%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 52 | 100% |
Revenue by Product & Service Category - Q1 FY2026
- Fanapt57.2%
- Hetlioz30.8%
- Ponvory12%
Revenue by Product & Service Category - Q1 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Fanapt | $ 30 | 57.2% |
| Hetlioz | $ 16 | 30.8% |
| Ponvory | $ 6 | 12% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Vanda Pharmaceuticals Inc
Vanda Pharmaceuticals is a biopharmaceutical company that is focused on developing a range of products for the treatment of central nervous system disorders. The company is headquartered in Washington, DC, and was founded in 2002 by Mihael H. Polymeropoulos and Argeris N. Karabelas.
The company has a deep pipeline of products that includes both small molecules and biologics. Its lead product is Fanapt, which is the first and only FDA-approved drug for the treatment of schizophrenia. It is also developing a range of products for the treatment of other neurological disorders such as Huntington's disease, jet lag, and sleep disorders.
Vanda Pharmaceuticals is known for its innovative approach to drug development, using cutting-edge technology and scientific methods to create new products that have the potential to transform the lives of patients. The company's researchers draw on a range of disciplines, including genetics, neurobiology, and pharmacology, to find new targets and develop new drugs.
Over the years, Vanda Pharmaceuticals has received numerous awards and recognitions for its work. In 2010, the company was recognized as one of the fast-growing private companies in the US by Inc. Magazine. In 2013, it received the Ernst & Young Entrepreneur of the Year Award.
The company has a strong financial position, with a market capitalization of approximately $800 million as of 202 Its stock is traded on the NASDAQ exchange under the symbol VNDA.
In terms of its corporate culture, Vanda Pharmaceuticals is committed to creating a supportive and collaborative work environment. The company values diversity, and its employees come from a range of backgrounds and nationalities. It is also committed to giving back to the community, with a focus on supporting healthcare initiatives and promoting education and scientific research.
Overall, Vanda Pharmaceuticals is an important player in the biopharmaceutical industry, with a reputation for innovation, scientific excellence, and a commitment to improving the lives of patients.
The company has a deep pipeline of products that includes both small molecules and biologics. Its lead product is Fanapt, which is the first and only FDA-approved drug for the treatment of schizophrenia. It is also developing a range of products for the treatment of other neurological disorders such as Huntington's disease, jet lag, and sleep disorders.
Vanda Pharmaceuticals is known for its innovative approach to drug development, using cutting-edge technology and scientific methods to create new products that have the potential to transform the lives of patients. The company's researchers draw on a range of disciplines, including genetics, neurobiology, and pharmacology, to find new targets and develop new drugs.
Over the years, Vanda Pharmaceuticals has received numerous awards and recognitions for its work. In 2010, the company was recognized as one of the fast-growing private companies in the US by Inc. Magazine. In 2013, it received the Ernst & Young Entrepreneur of the Year Award.
The company has a strong financial position, with a market capitalization of approximately $800 million as of 202 Its stock is traded on the NASDAQ exchange under the symbol VNDA.
In terms of its corporate culture, Vanda Pharmaceuticals is committed to creating a supportive and collaborative work environment. The company values diversity, and its employees come from a range of backgrounds and nationalities. It is also committed to giving back to the community, with a focus on supporting healthcare initiatives and promoting education and scientific research.
Overall, Vanda Pharmaceuticals is an important player in the biopharmaceutical industry, with a reputation for innovation, scientific excellence, and a commitment to improving the lives of patients.
Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for central nervous system (CNS) disorders. The company operates within the pharmaceuticals sector, primarily focusing on neurological and psychiatric disorders, presenting a robust product portfolio and a strong commitment to research and development.
Segments
Vanda Pharmaceuticals operates primarily as a single operating segment. This segment encompasses the research, development, manufacturing, marketing, and sales of pharmaceutical products specifically targeting CNS disorders. The companys concentrated efforts enable streamlined operations that enhance its ability to innovate within its specialized therapeutic area.
Products
Vanda Pharmaceuticals offers several key products, each aimed at addressing specific CNS-related conditions:
1. Hetlioz (tasimelteon):
Hetlioz is a prescription medication indicated for the treatment of Non-24 Sleep-Wake Disorder (Non-24), a condition primarily affecting individuals who are totally blind, preventing them from synchronizing their internal clock with the 24-hour day. Hetlioz acts on the body’s melatonin receptors, helping to regulate circadian rhythms and improve sleep patterns. It was groundbreaking as the first FDA-approved treatment specifically for Non-24, providing a new avenue of therapy for affected patients.
2. Fanapt (iloperidone):
Fanapt is prescribed for adults suffering from schizophrenia, a chronic and severe mental disorder that alters how a person thinks, feels, and behaves. The drug functions by modulating the levels of neurotransmitters in the brain, particularly dopamine and serotonin, which are critical in mood regulation and thought processes. Fanapt has been an important addition to the treatment landscape for schizophrenia, providing an alternative for patients who may not respond adequately to other antipsychotic medications.
3. Tradipitant:
Tradipitant is an investigational drug being explored for multiple conditions, including pruritus (chronic itching), gastroparesis (delayed gastric emptying), and motion sickness. The drug, a new molecule believed to act through neurokinin-1 (NK1) receptor antagonism, has generated interest due to its potential to provide relief from these diverse conditions. Its development signifies Vanda’s commitment to addressing unmet medical needs across various indications.
4. VTR-297:
VTR-297 is an investigational product focused on treating sleep and mood disorders. While specific details regarding its mechanism and therapeutic application are still under research, the development of VTR-297 underscores Vanda’s ongoing dedication to advancing treatment modalities in the psychiatry and neurology spheres.
Services
Vanda Pharmaceuticals enhances its product offerings through a range of services that support both healthcare providers and patients:
1. Research and Development:
Vanda invests substantially in R&D, aiming to discover and develop novel treatment options for CNS disorders. The company employs a dedicated team of scientists and researchers who conduct clinical trials, process optimization, and investigation of new therapeutic pathways to enhance treatment efficacy and safety.
2. Manufacturing:
Vanda ensures that its products are produced to the highest standards of quality. This includes possessing its own manufacturing facilities and adhering to stringent Good Manufacturing Practices (GMP). This commitment to quality control guarantees that every product released to the market is effective, safe, and meets rigorous regulatory standards.
3. Marketing and Sales:
The company has a robust marketing and sales strategy to promote its products. Vanda’s commercial team collaborates closely with healthcare professionals and institutions to facilitate education on its products, ensuring that accurate information is disseminated regarding their usage and benefits. The team is vital in building trust and awareness within the healthcare community to promote patient access to its therapies.
4. Patient Support:
Vanda Pharmaceuticals offers comprehensive patient support services tailored to assist individuals in accessing and utilizing its products. This includes assistance with medication affordability, navigation through insurance processes, and provision of educational resources. The patient support programs are designed to empower patients and their families, ensuring that they receive the necessary information and assistance throughout their treatment journey.
With a dedicated focus on addressing the needs of patients with CNS disorders, Vanda Pharmaceuticals Inc. continues to innovate and expand its product portfolio while providing essential services that enhance patient care and treatment outcomes.
Segments
Vanda Pharmaceuticals operates primarily as a single operating segment. This segment encompasses the research, development, manufacturing, marketing, and sales of pharmaceutical products specifically targeting CNS disorders. The companys concentrated efforts enable streamlined operations that enhance its ability to innovate within its specialized therapeutic area.
Products
Vanda Pharmaceuticals offers several key products, each aimed at addressing specific CNS-related conditions:
1. Hetlioz (tasimelteon):
Hetlioz is a prescription medication indicated for the treatment of Non-24 Sleep-Wake Disorder (Non-24), a condition primarily affecting individuals who are totally blind, preventing them from synchronizing their internal clock with the 24-hour day. Hetlioz acts on the body’s melatonin receptors, helping to regulate circadian rhythms and improve sleep patterns. It was groundbreaking as the first FDA-approved treatment specifically for Non-24, providing a new avenue of therapy for affected patients.
2. Fanapt (iloperidone):
Fanapt is prescribed for adults suffering from schizophrenia, a chronic and severe mental disorder that alters how a person thinks, feels, and behaves. The drug functions by modulating the levels of neurotransmitters in the brain, particularly dopamine and serotonin, which are critical in mood regulation and thought processes. Fanapt has been an important addition to the treatment landscape for schizophrenia, providing an alternative for patients who may not respond adequately to other antipsychotic medications.
3. Tradipitant:
Tradipitant is an investigational drug being explored for multiple conditions, including pruritus (chronic itching), gastroparesis (delayed gastric emptying), and motion sickness. The drug, a new molecule believed to act through neurokinin-1 (NK1) receptor antagonism, has generated interest due to its potential to provide relief from these diverse conditions. Its development signifies Vanda’s commitment to addressing unmet medical needs across various indications.
4. VTR-297:
VTR-297 is an investigational product focused on treating sleep and mood disorders. While specific details regarding its mechanism and therapeutic application are still under research, the development of VTR-297 underscores Vanda’s ongoing dedication to advancing treatment modalities in the psychiatry and neurology spheres.
Services
Vanda Pharmaceuticals enhances its product offerings through a range of services that support both healthcare providers and patients:
1. Research and Development:
Vanda invests substantially in R&D, aiming to discover and develop novel treatment options for CNS disorders. The company employs a dedicated team of scientists and researchers who conduct clinical trials, process optimization, and investigation of new therapeutic pathways to enhance treatment efficacy and safety.
2. Manufacturing:
Vanda ensures that its products are produced to the highest standards of quality. This includes possessing its own manufacturing facilities and adhering to stringent Good Manufacturing Practices (GMP). This commitment to quality control guarantees that every product released to the market is effective, safe, and meets rigorous regulatory standards.
3. Marketing and Sales:
The company has a robust marketing and sales strategy to promote its products. Vanda’s commercial team collaborates closely with healthcare professionals and institutions to facilitate education on its products, ensuring that accurate information is disseminated regarding their usage and benefits. The team is vital in building trust and awareness within the healthcare community to promote patient access to its therapies.
4. Patient Support:
Vanda Pharmaceuticals offers comprehensive patient support services tailored to assist individuals in accessing and utilizing its products. This includes assistance with medication affordability, navigation through insurance processes, and provision of educational resources. The patient support programs are designed to empower patients and their families, ensuring that they receive the necessary information and assistance throughout their treatment journey.
With a dedicated focus on addressing the needs of patients with CNS disorders, Vanda Pharmaceuticals Inc. continues to innovate and expand its product portfolio while providing essential services that enhance patient care and treatment outcomes.